2019-11-11T11:37:56-08:00 2018-12-31 390919055 Ritz Holman LLP 330 E Kilbourn Ste 550 Milwaukee WI 532023144 990 2018-01-01 391554806 SOCIETY FOR IMMUNOTHERAPY OF CANCER INC SOCI 4142712456 555 E WELLS STREET MILWAUKEE WI 53202 KIM A MARGOLIN MD SECR/TREASURER 2019-11-11 true KATY L SOMMER P00273273 4142711451 2018 2020-03-31 21:24:44Z Lisa H Butterfield PhD 555 E WELLS STREET 1100 MILWAUKEE WI 53202 13661709 false false X www.sitcancer.org X 1986 WI TO IMPROVE CANCER PATIENT OUTCOMES BY ADVANCING THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH OUR CORE VALUES OF INTERACTION/INTEGRATION, INNOVATION, TRANSLATION AND LEADERSHIP IN THE FIELD. SITC AIMS TO MAKE CANCER IMMUNOTHERAPY A STANDARD OF CARE AND THE WORD "CURE" A REALITY FOR CANCER PATIENTS EVERYWHERE. 13 13 0 13 89475 63392 6286542 5183258 5225535 8211680 39107 116192 111389 110886 11662573 13622016 1645270 724673 0 9500 7000 0 0 7353069 10650177 9007839 11381850 2654734 2240166 13410643 14883434 1733967 966592 11676676 13916842 X TO IMPROVE CANCER PATIENT OUTCOMES BY ADVANCING THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH OUR CORE VALUES OF INTERACTION/INTEGRATION, INNOVATION, TRANSLATION AND LEADERSHIP IN THE FIELD. SITC AIMS TO MAKE CANCER IMMUNOTHERAPY A STANDARD OF CARE AND THE WORD "CURE" A REALITY FOR CANCER PATIENTS EVERYWHERE. false false 5187587 6005380 SITC's 33rd Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. The intended audience for this program included U.S. and international researchers, regulators and health care professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals. 3146576 Workshop / Forward Fund / AMAP Other Programs / Interim Program / Sparkathon Program / Journal / Other Program Services 1226503 131000 84375 THE ADVANCES IN CANCER IMMUNOTHERAPY (ACI) REGIONAL SERIES HOSTED FIFTEEN REGIONAL CME-, CNE- AND CPE-CERTIFIED PROGRAMS IN 2018. THE SERIES WAS DESIGNED TO PROVIDE EDUCATION TO PATIENT CARE PROVIDERS AND OTHERS WHO WISH TO LEARN THE BASIC PRINCIPLES OF TUMOR IMMUNOLOGY AND IMMUNOTHERAPY, AND TO IMPROVE THEIR ABILITY TO INTEGRATE IMMUNOTHERAPY INTO STATE-OF-THE-ART CLINICAL MANAGEMENT FOR THEIR PATIENTS. THIS INTENDED AUDIENCE INCLUDES CLINICAL ONCOLOGISTS, REGISTERED NURSES, NURSE PRACTITIONERS, PHARMACISTS, EMERGENCY PHYSICIANS, ALLIED HEALTH PROFESSIONALS, OTHER PATIENT CARE PROVIDERS, STUDENTS AND PATIENT ADVOCATES. 674670 10235336 true true false false false false false false false false true false false false false true true false false true true true true false true false false true true false false false false false false false false false false false false false false false false false false false false false true 78 0 true 0 false true true false false false false false false 0 false false false false false false false false false false false false X 13 13 false true true false true true true true true false false true true true true true true true true false X Executive Director Inc 4142766445 555 E Wells St Suite 1100 MILWAUKEE WI 53202 LEISHA A EMENS MD PHD Director 1.00 0.00 X 2000 0 0 CHARLES G DRAKE MD PHD Director 1.00 0.00 X 0 0 0 JEROME GALON PHD Director 1.00 0.00 X 0 0 0 KRISTEN HEGE MD Director 1.00 0.00 X 0 0 0 PAOLO A ASCIERTO MD Director 1.00 0.00 X 0 0 0 HOWARD KAUFMAN MD IMM. PAST PRES. 1.00 0.00 X 3000 0 0 KIM A MARGOLIN MD SECR/TREASURER 5.00 0.00 X X 0 0 0 Lisa H Butterfield PhD President 5.00 0.00 X X 2000 0 0 DOUGLAS MCNEEL MD PHD Director 1.00 0.00 X 0 0 0 MARIO SZNOL MD Vice President 5.00 0.00 X X 0 0 0 DAVID KAUFMAN MD PHD Director 1.00 0.00 X 0 0 0 Pamela S Ohashi PhD Director 1.00 0.00 X 0 0 0 Samir N Khleif MD Director 1.00 0.00 X 0 0 0 7000 0 false false false EXECUTIVE DIRECTOR INC 555 E WELLS ST STE 1100 MILW WI 53202 MANAGEMENT 4024838 CORNERSTONE GOVERNMENT AFFAIRS INC 300 INDEPENDENCE AVE SE WASHINGTON DC 20003 CONSULTING 152000 BIG VOICE COMMUNICATIONS LLC 310 YALE AVENUE NEW HAVEN CT 06515 PUBLIC RELATIONS 127731 3 20000 5163258 5183258 AMAP Programs 900099 372416 372416 Membership Dues & Assessments 900099 454925 454925 Registration-Annual Meet 900099 5923380 5923380 Registration-Collaborativ 900099 534551 534551 Registration-Primer 900099 411425 411425 514983 514983 8211680 116192 116192 0 0 0 0 25280 20000 36150 -10870 -10870 0 19499 3543 15956 15956 Advertising 541800 82000 82000 Job Posting 541800 7475 7475 MISCELLANEOUS 900099 16325 16325 105800 13622016 8243961 89475 105322 514238 514238 195060 195060 15375 15375 0 7000 7000 0 0 0 0 0 4024838 3148151 876687 3700 3700 12750 12750 0 0 0 0 9496 9496 25279 25279 322544 303826 18718 0 0 0 0 5895101 5829983 65118 0 0 34641 34641 5720 5720 Journal 169683 169683 MEMBERSHIP DEVELOPMENT 90799 90799 Website 19927 19927 UBI TAXES 18320 18320 17379 17379 11381850 10235336 1146514 0 2726131 3602240 9268291 9856501 623737 584000 469053 302667 0 0 0 1529 1261 176107 443931 28836 19162 17828 9674 0 0 0 58921 32434 69046 50726 13410643 14883434 1607392 692247 126575 274345 1733967 966592 X 9133796 11244989 2542880 2671853 11676676 13916842 13410643 14883434 2240166 X false true X true false X 2058834 5234591 6468200 6657542 5638183 26057350 1674771 3038030 3938672 4867041 7756755 21275269 0 0 0 3733605 8272621 10406872 11524583 13394938 47332619 1343157 3829500 5155200 4287500 4265000 18880357 0 1343157 3829500 5155200 4287500 4265000 18880357 28452262 2810 2883 3234 39107 116192 164226 0 2810 2883 3234 39107 116192 164226 85900 72393 228019 78547 83218 548077 4833 16345 7989 10433 16325 55925 3827148 8364242 10646114 11652670 13610673 48100847 0.59150 0.56340 0.00340 0.00130 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 28836 19162 9674 9674 X 13661709 39693 39693 13622016 13622016 11421543 39693 39693 11381850 11381850 Part X : FIN48 Footnote The Organization is exempt from income tax under Section 501(c)(3) of the Internal Revenue Code and is classified as other than a private foundation. However, income from certain activities (primarily advertising income) not directly related to the Organizations tax exempt purpose is subject to taxation as unrelated business income. Unrelated business income tax expense for the year ended December 31, 2018, was $18,320. An unrelated business income tax deposit of $50,726 was recorded as of December 31, 2018.Management has reviewed all tax positions recognized in previously filed tax returns and those expected to be taken in future tax returns. As of December 31, 2018, the Organization had no amounts related to unrecognized income tax benefits and no amounts related to accrued interest and penalties. The Organization does not anticipate any significant changes to unrecognized income tax benefits over the next year. Part XI, Line 2d: Other revenue amounts included in F/S but not included on form 990 COST OF GOOD SOLD INCLUDED IN EXPENSES $3543 FUNDRAISING EVENT EXPENSE INCLUDED IN RE $36150 Part XII, Line 2d: Other expenses and losses per audited F/S COST OF GOODS SOLD INCLUDED IN EXPENSES $3543 FUNDRAISING EVENT EXPENSE INCLUDED IN RE $36150 false MIDDLE EAST & NORTH AFRICA 0 1 PROGRAM SERVICES JOURNAL HONORARIUM 625 EUROPE 0 5 PROGRAM SERVICES TRAVEL AWARD/JOURNAL HONORS 14750 6 6 15375 15375 EUROPE JOURNAL HONORARIUM 2000 WIRE TRANSFE 1 JITC HONORARIUM EUROPE 2 12000 WIRE TRANSFER false false false false false false X false FORWARD FUND HOUSE OF BLUES FUNDRAISER 45280 20000 25280 1815 28574 5761 45280 20000 25280 1815 28574 5761 36150 -10870 true DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 501(C)(3) 100000 0 FELLOWSHIP AWARD FRED HUTCHINSON CANCER CTR 1100 FAIRVIEW AVE N MS J6-330 SEATTLE WA 98109 237156071 501(C)(3) 50000 0 FELLOWSHIP AWARD MASSACHUSETTS GEN HOSPITAL 149 13TH STREET ROOM 7219 CHARLESTOWN MA 02129 042697983 501(C)(3) 50000 0 ABSTRACT TRAVEL AWARD MELANOMA RESEARCH ALLIANCE 1101 NEW YORK AVE WASHINGTON DC 20005 261636099 501(C)(3) 150000 0 SITC-YOUNG INVESTIGATOR MEMORIAL SLOAN-KETTERING 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 100000 0 FELLOWSHIP AWARD TRUSTEES OF U OF PENN 3451 Walnut ST Room P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 50000 0 FELLOWSHIP AWARD 6 0 PRESIDENTAL AWARD 2 2000 PRESIDENTIAL TRAVEL 3 2234 ABSTRACT TRAVEL 23 16826 SMALLEY AWARD 1 5000 ACI HONORARIUM 142 124000 MEDSCAPE HONORARIA 13 35000 JOURNAL HONORARIA 5 10000 Grantmaker's Description of How Grants are Used THE PRESIDENTIAL AWARD AND PRESIDENTIAL TRAVEL AWARDS ARE PRESENTED TO THE TOP FOUR SELECTED ABSTRACTS AUTHORED BY YOUNG INVESTIGATORS. THE JITC BEST PAPER AWARDS ARE PRESENTED TO THE BEST PAPER AUTHORS SUBMITTED IN THE CLINICAL/TRANSLATIONAL AND BASIC SCIENCE CATEGORIES. THE SITC ABSTRACT TRAVEL AWARDS ARE PRESENTED TO THE TOP SCORING ABSTRACTS FROM YOUNG INVESTIGATORS. THE AWARDS ARE PRESENTED DURING THE ANNUAL MEETING AND THE TRAVEL AWARDS RECIPIENTS ARE REIMBURSED FOR THEIR TRAVEL EXPENSES AFTER QUALIFING RECEIPTS ARE SUBMITTED UP TO THE PRE-DETERMINED AWARD LIMIT. JUDGING OF THE ABSTRACT PRESENTATIONS AND AWARDS ARE DONE BY A COMMITTEE OF SITC LEADERSHIP. Form 990, Part III, Line 4d: Other Program Services Description OTHER PROGRAM SERVICES 4: Workshop / Forward Fund / AMAP Other Programs / Interim Program / Sparkathon Program / Journal / Other Program Services Form 990, Part VI, Line 3: Description of Delegated Duties to Management Company SITC IS IN CONTRACT WITH EXECUTIVE DIRECTOR, INC., AN ASSOCIATION MANAGEMENT COMPANY. Form 990, Part VI, Line 4: Description of Significant Changes to Organizational Documents THE BYLAWS WERE AMENDED IN THE FOLLOWING AREAS:Classes of Membership: The Society shall consist of nine classes of members: Regular, Emeritus, Affiliate, Student and Scientist-in-Training, Allied Health, Nurse and Advanced Practice Provider, Patient and Patient Advocate, Pharmacist and Corporate.Membership Dues: The dues for Regular, Affiliate, Student and Scientist-in-Training, Allied Health, Nurse and Advanced Practice Provider, Patient and Patient Advocate, Pharmacist and Corporate members shall be as determined by the Board of Directors from time to time. Form 990, Part VI, Line 6: Explanation of Classes of Members or Shareholder THE SOCIETY CONSISTS OF NINE CLASSES OF MEMBERSHIP: REGULAR, EMERITUS, AFFILIATE, STUDENT AND SCIENTIST-IN-TRAINING, ALLIED HEALTH, NURSE AND ADVANCED PRACTICE PROVIDER, PATIENT AND PATIENT ADVOCATE, PHARMACIST AND CORPORATE. Form 990, Part VI, Line 7a: How Members or Shareholders Elect Governing Body REGULAR AND EMERITUS MEMBERS IN GOOD STANDING ARE ENTITLED TO VOTE ON THE ELECTION OF THE OFFICERS-DIRECTORS OF THE SOCIETY. VOTING TAKES PLACE EACH YEAR AT THE ANNUAL SCIENTIFIC AND BUSINESS MEETING UNLESS PREVIOUSLY HELD BY WRITTEN BALLOT. Form 990, Part VI, Line 7b: Describe Decisions of Governing Body Approval by Members or Shareholders ONLY REGULAR AND EMERITUS MEMBERS IN GOOD STANDING ARE ENTITLED TO VOTE ON ALL MATTERS TO BE VOTED ON BY MEMBERS OF THE SOCIETY. Form 990, Part VI, Line 11b: Form 990 Review Process THE FORM 990 AND ALL APPLICABLE SCHEDULES ARE DISTRIBUTED TO THE FINANCE COMMITTEE FOR REVIEW AND DISCUSSION. THE FINANCE COMMITTEE RECOMMENDS THE BOARD TO APPROVE THE FORM 990. ONCE APPROVED, THE 990 TAX FORM IS SIGNED BY A SELECTED OFFICER AND FILED WITH THE IRS. Form 990, Part VI, Line 12c: Explanation of Monitoring and Enforcement of Conflicts MEMBERS OF THE BOARD OF DIRECTORS, EXECUTIVE COUNCIL, AND COMMITTEE CHAIRS ARE COVERED UNDER THE POLICY. ANY POSSIBLE CONFLICTS OF INTEREST DISCLOSED ARE REVIEWED BY THE EXECUTIVE DIRECTOR AND ARE BROUGHT FORWARD TO THE BOARD OF DIRECTORS FOR FURTHER INVESTIGATION, REVIEW AND DETERMINATION OF THE APPROPRIATE DISCIPLINARY ACTIONS. POSSIBLE CONFLICTS DISCLOSED BEFORE A MEETING ARE REVIEWED BY THE PRESIDENT, PRESIDING OFFICER OR COMMITTEE CHAIR PERSON TO DETERMINE WHETHER OR NOT THE CONFLICT IS INAPPROPRIATE FOR THE MEMBER TO CONTRIBUTE TO THE CONVERSATION. THE RESTRICTIONS IMPOSED ON PERSONS WITH A CONFLICT ARE WITHDRAWAL FROM DISCUSSION AND VOTING ON THE MATTER. Form 990, Part VI, Line 15a: Compensation Review & Approval Process - CEO, Top Management SITC IS MANAGED BY EXECUTIVE DIRECTOR, INC., A FOR-PROFIT MANAGEMENT COMPANY. SITC HAS NO OFFICIAL EMPLOYEES BECAUSE ALL STAFF ASSIGNED TO SITC ARE EMPLOYEES OF THE MANAGEMENT COMPANY. SITC DOES NOT COMPENSATE ANY OF ITS OFFICERS OR BOARD MEMBERS. THE SOCIETY ALSO DOES NOT HAVE ANYONE THAT FITS THE DEFINITION OF A KEY EMPLOYEE. Form 990, Part VI, Line 15b: Compensation Review and Approval Process for Officers and Key Employees SITC DOES NOT COMPENSATE ANY OF ITS OFFICERS OR BOARD MEMBERS. THE SOCIETY ALSO DOES NOT HAVE ANYONE THAT FITS THE DEFINITION OF A KEY EMPLOYEE. Form 990, Part VI, Line 19: Other Organization Documents Publicly Available SITC MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FORM 990 AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. REQUEST SHOULD BE MADE TO THE SITC OFFICE AND DOCUMENTS ARE PROVIDED WITHIN A REASONABLE TIMEFRAME VIA MAIL OR E-MAIL. THE BYLAWS CAN ALSO BE FOUND ON THE SITC WEBSITE.